Adverum Biotechnologies (ADVM) Prices 9.5M Share Common Offering at $13.75/Sh

Adverum Biotechnologies (ADVM) Ramps 17% Despite Pending Stock Offering

Adverum Biotechnologies (NASDAQ: ADVM) gains 17% despite pending $100M stock offering

Adverum Biotechnologies (ADVM) PT Raised to $13 at SunTrust

SunTrust analyst Joon Lee raised the price target on Adverum Biotechnologies (NASDAQ: ADVM) to $13.00 (from $8.00) while maintaining a Hold rating.... More

Adverum Biotechnologies (ADVM) to Offer $100M in Stock

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced that it has commenced an underwritten public offering of $100 million of its common stock. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common... More

UPDATE: Chardan Capital Markets Upgrades Adverum Biotechnologies (ADVM) to Buy

(Updated - February 10, 2020 9:55 AM EST)

Chardan Capital Markets analyst Gbola Amusa upgraded Adverum Biotechnologies (NASDAQ: ADVM) from Neutral to Buy with a price target of $20.00.

The analyst commented, "In a population of patients with frequent anti-VEGF injections at baseline, Adverum, with combined Cohort 1 and 2 data, has shown 10/12 (83%)... More

Pre-Open Stock Movers 2/10: (VTVT) (EPC) (TSLA) Higher (ABUS) (BHVN) (LLY) Lower (more...)

Today's Pre-Open Stock Movers

vTv Therapeutics Inc. (Nasdaq: VTVT) 79.5% HIGHER; announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D). TTP399 is a novel, liver-selective glucokinase activator taken once a day. The 12-week trial investigated the efficacy and safety of 800 mg of TTP399 compared with placebo in 85 people with type 1 diabetes on optimized insulin therapy. The study was conducted with support from JDRF International (JDRF), the leading provider of T1D research funding... More

Adverum Biotechnologies (ADVM) Highlights New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Adverum Biotechnologies, Inc. (NASDAQ: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new interim clinical data from the OPTIC Phase 1 dose-ranging clinical trial of ADVM-022 intravitreal injection gene therapy. OPTIC includes treatment-experienced patients with wet age-related macular degeneration (AMD). The data are being presented today by David S. Boyer, M.D., senior partner, Retina-Vitreous... More